Enrollment Update

EXPERIENCE-204 (adolescent) and EXPERIENCE-301 (adult) clinical trials are now fully enrolled. We are incredibly grateful to the entire FXS community for helping us reach this important milestone.
We recognize the ongoing pursuit of new drugs for FXS has been challenging and we are grateful for the opportunity to be part of this journey with you.
Please know that completing enrollment in EXPERIENCE-204 and 301 does not affect EXPERIENCE-302 (our open-label study), through which participants will continue to receive the investigational study drug. EXPERIENCE-302 remains open for previously enrolled participants as well as participants who complete EXPERIENCE-204 or 301.
We look forward to sharing the study findings later this year.
Warm regards,
Chief Medical Officer
Shionogi & Co., Ltd.
If you have any questions about the EXPERIENCE clinical trials, please contact medinfo@shionogi.com or 1-800-849-9707.
You can also view additional information about EXPERIENCE here and sign up for updates from Shionogi here.